These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25998230)

  • 21. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Points to Consider in Designing and Conducting Juvenile Toxicology Studies.
    Kim NN; Parker RM; Weinbauer GF; Remick AK; Steinbach T
    Int J Toxicol; 2017; 36(4):325-339. PubMed ID: 28466670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds.
    Ahuja V; Bokan S; Sharma S
    Drug Discov Today; 2017 Jan; 22(1):127-132. PubMed ID: 27644594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling.
    Tassinari MS; Benson K; Elayan I; Espandiari P; Davis-Bruno K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):261-5. PubMed ID: 21594977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.
    Rose K; Kopp MV
    Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of pharmacological treatment of obesity in children. A European regulatory perspective.
    Karres J; Tomasi P; Saint Raymond A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 May; 54(5):570-6. PubMed ID: 21547648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing drugs for pediatric use: a role for juvenile animal studies?
    Baldrick P
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):381-9. PubMed ID: 15135215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions.
    Everitt JI
    Toxicol Pathol; 2015 Jan; 43(1):70-7. PubMed ID: 25351920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-Informed Reverse and Forward Translation of Safety Risks in Drug Development.
    Mettetal JT
    Clin Pharmacol Ther; 2018 Feb; 103(2):199-201. PubMed ID: 29194584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The great barrier belief: The blood-brain barrier and considerations for juvenile toxicity studies.
    Schmitt G; Parrott N; Prinssen E; Barrow P
    Reprod Toxicol; 2017 Sep; 72():129-135. PubMed ID: 28627392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Paediatric Medicines Development: Have Paediatric Investigation Plans Lost Heart?
    Faulkner B; Delgado-Charro MB
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.